Close Menu

Cardiovascular Disease

News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.

The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.

The technology underlying the test was developed by Dutch firm Minicare, which was acquired by Siemens in 2019.

The company signed a non-exclusive license for Zora's ceramide markers and plans to launch a test based on the markers as early as next year.

Later this year, the inherited cardiovascular disease clinic also plans to implement a preventive genomics program with polygenic risk score and PGx testing.

The iQ Group Global is integrating the Wyss Institute's technology with its own organic thin-film biosensor platform for SARS-CoV-2 serology testing.